Testing effectiveness (Phase 2)Looking for participantsNCT06534437
What this trial is testing
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
Who this might be right for
Non-Hodgkin Lymphoma, B-cell
Ryvu Therapeutics SA 178